Daiwa Securities Group Downgrades Abbott Laboratories (NYSE:ABT) to Neutral

Abbott Laboratories (NYSE:ABT) was downgraded by stock analysts at Daiwa Securities Group from an “outperform” rating to a “neutral” rating in a report released on Wednesday, MarketBeat Ratings reports. They presently have a $92.00 target price on the healthcare product maker’s stock. Daiwa Securities Group’s price objective indicates a potential downside of 0.49% from the company’s current price.

ABT has been the topic of a number of other reports. Benchmark cut their target price on Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating on the stock in a report on Friday, April 17th. Leerink Partners cut their target price on Abbott Laboratories from $119.00 to $106.00 and set a “market perform” rating on the stock in a report on Tuesday. Citigroup cut their target price on Abbott Laboratories from $136.00 to $108.00 and set a “buy” rating on the stock in a report on Friday, April 17th. Stifel Nicolaus cut their target price on Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating on the stock in a report on Friday, April 17th. Finally, JPMorgan Chase & Co. cut their target price on Abbott Laboratories from $123.00 to $110.00 and set an “overweight” rating on the stock in a report on Friday, April 17th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $119.43.

Abbott Laboratories Stock Performance

Shares of ABT stock opened at $92.45 on Wednesday. The company has a market cap of $161.02 billion, a price-to-earnings ratio of 25.90, a price-to-earnings-growth ratio of 1.53 and a beta of 0.79. Abbott Laboratories has a 52 week low of $90.72 and a 52 week high of $139.06. The company has a quick ratio of 1.18, a current ratio of 1.58 and a debt-to-equity ratio of 0.19. The firm has a 50 day moving average of $106.39 and a 200-day moving average of $117.64.

Abbott Laboratories (NYSE:ABT) last issued its earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.14 by $0.01. Abbott Laboratories had a return on equity of 17.71% and a net margin of 13.90%.The company had revenue of $11.16 billion for the quarter, compared to analysts’ expectations of $10.99 billion. During the same period last year, the business earned $1.09 EPS. Abbott Laboratories’s quarterly revenue was up 7.8% compared to the same quarter last year. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. On average, equities analysts forecast that Abbott Laboratories will post 5.49 earnings per share for the current year.

Insider Buying and Selling at Abbott Laboratories

In other Abbott Laboratories news, VP John A. Jr. Mccoy sold 585 shares of the firm’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $67,614.30. Following the transaction, the vice president directly owned 24,628 shares in the company, valued at approximately $2,846,504.24. This trade represents a 2.32% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Daniel Gesua Sive Salvadori sold 885 shares of the firm’s stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $102,288.30. Following the transaction, the executive vice president owned 146,377 shares in the company, valued at approximately $16,918,253.66. This trade represents a 0.60% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 3,055 shares of company stock worth $353,097. 0.46% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Abbott Laboratories

Several large investors have recently bought and sold shares of the stock. Gemmer Asset Management LLC boosted its stake in shares of Abbott Laboratories by 2.9% during the 3rd quarter. Gemmer Asset Management LLC now owns 2,750 shares of the healthcare product maker’s stock worth $368,000 after acquiring an additional 78 shares in the last quarter. Nia Impact Advisors LLC boosted its stake in shares of Abbott Laboratories by 2.2% during the 2nd quarter. Nia Impact Advisors LLC now owns 3,706 shares of the healthcare product maker’s stock worth $504,000 after acquiring an additional 79 shares in the last quarter. Global Financial Private Client LLC boosted its stake in shares of Abbott Laboratories by 3.3% during the 3rd quarter. Global Financial Private Client LLC now owns 2,469 shares of the healthcare product maker’s stock worth $331,000 after acquiring an additional 79 shares in the last quarter. Citizens & Northern Corp boosted its stake in shares of Abbott Laboratories by 0.4% during the 3rd quarter. Citizens & Northern Corp now owns 21,875 shares of the healthcare product maker’s stock worth $2,930,000 after acquiring an additional 79 shares in the last quarter. Finally, American National Bank of Texas boosted its stake in shares of Abbott Laboratories by 2.4% during the 4th quarter. American National Bank of Texas now owns 3,408 shares of the healthcare product maker’s stock worth $427,000 after acquiring an additional 79 shares in the last quarter. 75.18% of the stock is currently owned by institutional investors.

Key Stories Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Large-market tailwind: a new IoT medical‑devices market report forecasts strong secular growth for connected and remote-monitoring devices through 2036, supporting Abbott’s device franchises (long-term demand upside). IoT Medical Devices Market Research and Global Forecast Report 2026-2036
• Positive Sentiment: “Most oversold” commentary: coverage noting Abbott as one of the most oversold healthcare names may prompt value-oriented buying and short-covering, supporting near-term rebounds. Abbott is the most oversold healthcare stock as Q1 earnings roll on
• Neutral Sentiment: Elevated investor attention: Zacks and Yahoo note heavy search/interest in ABT, which can increase volatility and trading volume but doesn’t directly change fundamentals. Investors Heavily Search Abbott Laboratories (ABT)
• Neutral Sentiment: Competitive/industry note: unrelated coverage of Intuitive Surgical’s platform refresh highlights competitive dynamics in surgical robotics/devices — worth watching for competitive impact but not an immediate Abbott-specific catalyst. How ISRG Just Secured The U.S. Market
• Negative Sentiment: UBS trims price target to $135 — a reduction in analyst optimism that can cap upside and weigh on investor sentiment despite the company’s solid Q1. UBS Group Cuts Abbott Laboratories (NYSE:ABT) Price Target to $135.00
• Negative Sentiment: Argus issues a pessimistic forecast for ABT — adds to negative analyst noise and could pressure the stock if other firms follow suit. Argus Issues Pessimistic Forecast for Abbott Laboratories (NYSE:ABT) Stock Price
• Negative Sentiment: Daiwa downgrades ABT to neutral and sets a $92 target — implies limited near-term upside and may influence short‑term seller behavior. Finviz (Daiwa downgrade note)
• Negative Sentiment: Barclays lowers expectations for ABT — another bearish signal from the sell side that contributes to downward pressure on sentiment and potential re-rating risk. Barclays Has Lowered Expectations for Abbott Laboratories (NYSE:ABT) Stock Price

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.